Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Company Deals

Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration

Fineline Cube May 13, 2026
Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Fineline Cube May 13, 2026
Policy / Regulatory

Hong Kong to Launch FDA-Style Medical Products Regulation Center by Year-End, Creating Gateway for Chinese Innovative Drugs

Fineline Cube May 13, 2026
Company Drug

Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials

Fineline Cube May 13, 2026
Company Drug

Servier’s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma

Fineline Cube May 13, 2026
Company Drug

Sanofi’s Rilzabrutinib Shows Promise in IgG4-Related Disease Trial

Fineline Cube Jun 13, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) announced positive results from a Phase II study of...

Company Deals

Bayer Extends Genomics Partnership With Broad Institute for Cardiology Research

Fineline Cube Jun 13, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) and the US-based Broad Institute Inc. announced a...

Company Deals

Bayzed Health Launches HK IPO to Expand Cancer Care Services

Fineline Cube Jun 13, 2025

China-based Bayzed Health Group Inc. (HKG: 2609), a private healthcare provider specializing in oncology, has...

Company Deals

TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share

Fineline Cube Jun 13, 2025

China-headquartered TransThera Sciences (Nanjing) Inc. is preparing for an initial public offering (IPO) of 15.281...

Company Drug

BeOne Medicines Wins FDA Approval for Brukinsa Tablet Across All Five Indications

Fineline Cube Jun 13, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...

Company Deals Medical Device

Gene Solutions Partners with Topgen Biopharm to Advance Precision Oncology in Asia

Fineline Cube Jun 13, 2025

Vietnam-based Gene Solutions, a provider of genetic tests and non-invasive prenatal testing (NIPT) for women’s...

Company Deals

Suzhou’s MEI Medical Secures RMB 100M Funding for ePTFE Innovation

Fineline Cube Jun 13, 2025

Suzhou-based MEI Medical Technologies Co., Ltd., a medical device manufacturer specializing in peripheral vascular intervention,...

Company Drug

BMS Reports Positive POETYK PsA-1 Results for Sotyktu in Psoriatic Arthritis

Fineline Cube Jun 13, 2025

US-based Bristol-Myers Squibb (BMS; NYSE: BMY) announced positive results from the pivotal Phase III POETYK...

Company Drug

Lilly Launches Mounjaro Multi-Dose Pen in China for Diabetes and Weight Management

Fineline Cube Jun 13, 2025

US-based Eli Lilly & Co. (NYSE: LLY) announced the launch of Mounjaro (tirzepatide multi-dose prefilled...

Company Deals

XtalPi Acquires Liverpool ChiroChem to Boost AI-Driven Drug Discovery

Fineline Cube Jun 12, 2025

Shenzhen-based XtalPi Holdings Limited (HKG: 2228), an AI-driven pharmaceutical company, announced the complete acquisition of...

Company Deals

Shandong Boan Partners with Shanghai Pharma for BA5101 Diabetes Drug

Fineline Cube Jun 12, 2025

China-based Shandong Boan Biotechnology Co., Ltd (HKG: 6955) announced a strategic collaboration with Shanghai Pharmaceuticals...

Company Deals

GCCF and CTTQ Explore Collaboration to Expand Innovative Drug Access in Hong Kong

Fineline Cube Jun 12, 2025

Dr. Cheng Kam-chung, Founder and Chairman of the Greater China Cancer Foundation (GCCF), led a...

Company Drug

ImmVira Commences Phase II Trial for MVR-T3011 in High-Risk NMIBC

Fineline Cube Jun 12, 2025

Shenzhen-based ImmVira announced that it has administered the first patient dose in a global, multi-center...

Company Deals

Escugen Partners with SovranBio to Accelerate Development of Antibody-Drug Conjugates

Fineline Cube Jun 12, 2025

Shanghai Escugen, a China-based clinical-stage company specializing in innovative antibody-drug conjugate (ADC) development, announced a...

Company Medical Device

Varian Medical Systems Secures NMPA Approval for Ethos 2.0 AI Radiotherapy Platform

Fineline Cube Jun 12, 2025

US-based Varian Medical Systems (NYSE: VAR) announced that it has received marketing approval from China’s...

Company

Novo Nordisk China Restructures to Form New Obesity and Diabetes Department

Fineline Cube Jun 12, 2025

Danish pharmaceutical giant Novo Nordisk’s (NYSE: NVO) China unit announced an organizational restructuring, merging its...

Company Deals

Eli Lilly Partners with Juvena Therapeutics on Muscle Health AI Platform

Fineline Cube Jun 12, 2025

US-based Eli Lilly & Co. (NYSE: LLY) announced a global licensing and multi-target research collaboration...

Company Drug

Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation

Fineline Cube Jun 12, 2025

Japan-based Daiichi Sankyo (TYO: 4568) has registered a Phase I clinical trial on ClinicalTrials.gov for...

Medical Device Policy / Regulatory

NMPA Issues Immediate Guidelines for NGS-Related IVD Reagent Classification

Fineline Cube Jun 12, 2025

China’s National Medical Products Administration (NMPA) released the “Guidelines for Classification Definition of Next-Generation Sequencing...

Policy / Regulatory

China Updates Class 3 Hospital Accreditation Standards for 2025

Fineline Cube Jun 12, 2025

Last month, China’s National Health Commission officially issued the Class 3 Hospital Accreditation Standards (2025...

Posts pagination

1 … 144 145 146 … 665

Recent updates

  • Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform
  • Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials
  • Legend Biotech Reports 56% Q1 Revenue Growth to $305M, Driven by Carvykti Sales Surge and J&J Milestone Payment
  • Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms
  • Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Company Drug

Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials

Company

Legend Biotech Reports 56% Q1 Revenue Growth to $305M, Driven by Carvykti Sales Surge and J&J Milestone Payment

Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.